Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview David F. Chang, MD.

• Welcome to the Eyeluminaries podcast :10
• A review of the previous episode :30
• News and notes with John and Jim 1:15
• AMA president outlines 5 actions for policymakers to take to support physicians 1:20
• Aetna drops prior authorization requirement for cataract surgery 4:10
• Yutiq approved in China 6:21
• Lensar received FDA 510(k) clearance for its next-generation Ally adaptive cataract treatment system 8:55
• Introduction of David F. Chang, MD 10:30
• The interview 11:48
• How did EyeSustain develop and how can people become involved? 13:54
• What are you doing differently already in your surgery center or office to reduce waste? 18:27
• Tell us your thoughts on same-day bilateral cataract surgery and intracameral antibiotics 21:02
• What technological advancements do you see coming here from outside the U.S? 25:18
• An anecdote on parenting, baseball and myopia 31:16
• A preview of the next episode of Eyeluminaries 33:08

David F. Chang, MD, is a world-renowned cataract surgeon and innovator in the field. He is clinical professor of ophthalmology at the University of California, San Francisco, and is in private practice in Los Altos, Calif.

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.